Drug
Afimkibart clinical trials
Also written PF-06480605 and RO7790121.
Keep track of what changes. Save the afimkibart studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2026 (6)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2016 | 1 |
| 2020 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 5 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 0
Studies
Open first, then newest update. How each study uses afimkibart is read from its arms, and is right about nine times in ten.
Testing it · 17
- A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's DiseaseRecruitingPhase 3Hoffmann-La RocheNCT06819878Written as Afimkibart
- An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative ColitisRecruitingPhase 1Hoffmann-La RocheNCT07665723Written as Afimkibart
- An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid ArthritisRecruitingPhase 2Hoffmann-La RocheNCT07620392Written as Afimkibart
- A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)RecruitingPhase 2Hoffmann-La RocheNCT07137598Written as Afimkibart
- A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic DermatitisActive, not recruitingPhase 2Hoffmann-La RocheNCT07223697Written as Afimkibart
- A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's DiseaseRecruitingPhase 3Hoffmann-La RocheNCT07298421Written as Afimkibart
- A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative ColitisRecruitingPhase 3Hoffmann-La RocheNCT07158242Written as Afimkibart
- A Study to Assess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimkibart in Participants With Moderately to Severely Active Ulcerative ColitisRecruitingPhase 3Hoffmann-La RocheNCT07846683Written as Afimkibart
- A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's DiseaseRecruitingPhase 3Hoffmann-La RocheNCT06819891Written as Afimkibart
- A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver FibrosisActive, not recruitingPhase 1Hoffmann-La RocheNCT06903065Written as RO7790121
- A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative ColitisActive, not recruitingPhase 3Hoffmann-La RocheNCT06588855Written as Afimkibart
- Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's DiseaseActive, not recruitingPhase 2Hoffmann-La RocheNCT05910528Written as Afimkibart
- A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative ColitisActive, not recruitingPhase 3Hoffmann-La RocheNCT06589986Written as Afimkibart
- A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic DermatitisActive, not recruitingPhase 2Hoffmann-La RocheNCT06863961Written as Afimkibart
- Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.CompletedPhase 2Telavant, Inc.NCT02840721Written as PF-06480605
- Evaluation of Safety, Tolerability and Pharmacokinetics of Single Dose of PF-06480605 in Japanese Healthy ParticipantsCompletedPhase 1Telavant, Inc.NCT04269538Written as PF-06480605
- Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.CompletedPhase 1Telavant, Inc.NCT01989143Written as PF-06480605
Codes
What other systems call afimkibart · ClinicalTrials.gg INT017201
- UNII (FDA) LNU830UGAXAFIMKIBARTOne source FDA
- NCI Thesaurus C211786AfimkibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | LNU830UGAX | AFIMKIBART | One source FDA |
| NCI Thesaurus | C211786 | Afimkibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.